Search results for " activity" in Articles / App Notes
Article
Climate Change in Outsourcing
As 2013 draws to a close, the bio/pharmaceutical industry continues to be reshaped by changes in the business climate. Financial, political, and scientific developments that began 10 years ago conti…
Article
Bioprocessing Advances in Vaccine Manufacture
Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.
The vaccine industry, particularly, in major Western markets, continues to be dominated by a few majo…
Article
Report from the Eighth International Plasma Product Biotechnology Meeting Melia Salinas, Lanzarote, Spain
Report from the Lanzarote meeting May 13th – 17th, 2013
Yet another well-attended and successful Plasma Product Biotechnology (PPB) meeting has been held. The meeting focu…
Article
Regulatory Challenges in the QbD Paradigm
The authors demonstrate how an integrated model is helping to achieve regulatory flexibility. This article is part of a special section on biopharmaceutical trends.
With the dawn of the 2…
Article
QbD and PAT in Upstream and Downstream Processing
To gain perspective on the implementation of quality by design (QbD) and process analytical technology (PAT) in biopharmaceutical processing, BioPharm International spoke with Clinton Weber, as…
Article
Flexibility in Biopharmaceutical Manufacturing
At network level, particularly larger companies that have absorbed other companies and comprise multiple legacy facilities, adaptability to reconfigure networks has become an ongoing and continuous ac…
Article
Automated Concentration and Diafiltration of Multiple siRNA Samples
To effectively screen potential targets for in vivo activity, it is necessary to create an optimized workflow at the appropriate scale, capable of delivering 100 unique siRNA duplex targets per month.…
Article
Challenges for biosimilar developers: A conversation with Dr. Howard Levine about new FDA draft guidelines
So there’s obviously been a lot of activity behind the scenes, if you will, of companies approaching FDA even before the guidelines were published.”
Levine thinks that the first wave of biosimila…